Cognitive enhancement in combination with 'brain repair' may be optimal for the treatment of stimulant addiction

Comment

Jennifer M Loftis et al. Addiction. 2011 May.

. 2011 May;106(5):1021-2.

doi: 10.1111/j.1360-0443.2010.03354.x. Epub 2011 Mar 7.

No abstract available

Conflict of interest statement

Declarations of interest

None.

Cognitive enhancement as a pharmacotherapy target for stimulant addiction.
Sofuoglu M. Sofuoglu M. Addiction. 2010 Jan;105(1):38-48. doi: 10.1111/j.1360-0443.2009.02791.x. Addiction. 2010. PMID: 20078461 Free PMC article. Review.

1. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction. 2010;105:38–48. - PMC - PubMed
1. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008;96:222–32. - PMC - PubMed
1. Johnson BA, Ait-Daoud N, Elkashef AM, Smith EV, Kahn R, Vocci F, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of odansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol. 2008;11:1–14. - PubMed
1. Heinzerling KG, Swanson AN, Kim S, Cederblom L, Moe A, Ling W, et al. Randomized, double-blind, placebo controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010;109:20–9. - PMC - PubMed
1. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine. JAMA. 2009;301:1148–54. - PMC - PubMed